Rallybio price target lowered to $14 from $16 at Wedbush

Wedbush lowered the firm’s price target on Rallybio to $14 from $16 and keeps an Outperform rating on the shares following the Q3 financial report. All of Rallybio’s efforts remain on track, and the company continues to make good progress on its FNAIT natural history study, the analyst tells investors in a research note. Wedbush likes the opportunity for a compressed regulatory path in this indication should the Phase 2/3 data prove successful.